Roche launches low-volume lab-coagulation portfolio with the new cobas t 411 analyzer
Rotkreuz, 20th November 2015
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its new lab-coagulation solution, the cobas t 411 analyzer, is now available for countries accepting the CE Mark1.
The new cobas t 411 analyzer is a stand-alone lab coagulation system that is suitable for low-volume routine testing (up to 120 samples per day). With this launch, Roche has expanded their overall laboratory coagulation offering, giving laboratories further flexibility for their dedicated testing needs.
“We are entering into a new era of coagulation testing for Roche, through expansion of our coagulation solution and we will continue to develop systems which support our customer’s lab efficiency and productivity needs” said Jean-Claude Gottraux, Head of Roche Professional Diagnostics. “The cobas t 411 is the next foundation stone for Roche to become a total solution provider for coagulation testing in both the laboratory and at the Point of Care.”
The new cobas t 411 analyzer will enable customers to optimize their laboratory processes. It achieves this by allowing continuous loading of all samples, reagents and the cuvettes, which hold the required samples and reagents during testing. This will ultimately help reduce workflow interruption. The unique cuvette design, and readiness check prior to measurement, helps improve quality of results. The multimode cap piercing, which recognizes different sample cap types prior to sampling, gives flexibility and convenience. In addition, the analyzer has the highest reagent capacity on the market for reduced hands-on time, compared to other systems offered at low-volume coagulation laboratories.
1Local product availability may vary independently from CE Mark approval.
About the cobas t 411 analyzer and tests
Laboratory coagulation testing accounts for around one fifth of the total sample workload of the core laboratory.. The cobas t 411 analyzer serves low-volume central coagulation laboratories. Featuring innovative sample and reagent management concepts, the cobas t 411 coagulation analyzer may enable increased operator convenience and productivity. The analyzer offers cap-piercing as a standard feature, which maximizes throughput when combined with the five position rack-based sample handling. High on-board capacities for reagents and samples, along with continuous loading of reagents, samples and consumables, result in increased walk-away times. Efficient reagent use is optimized with on-board barcode scanning capability and cooled, tilted reagent racks. Patient safety is prioritized through the unique opto-mechanical detection principle by checking each sample before measurement, as well as the always available STAT port, whereby emergency samples can be immediately processed with test results returned in a timely fashion. These features provide a cost-effective tool for the daily coagulation needs of customers in the low-volume laboratory segment. The cobas t 411 analyzer is one part of the growing Roche coagulation solution, which also includes Point of Care coagulation testing. For more information, visit www.cobas.com or www.coaguchek.com.
About coagulation and coagulation monitoring
The coagulation system comprises the platelets and the plasma coagulation factors. Its main functions are the physiological “sealing” of vascular defects and, in the case of injuries, formation of the initial platelet plug. Additionally, the coagulation system reinforces the platelet plug with fibrin and, finally, clot retraction. Inhibitors bind excess activated clotting factors and thus prevent excessive growth of the thrombus. After injury of a blood vessel, bleeding is temporarily stopped by formation of the primary thrombus (platelet plug) within a few minutes. The platelet plug is an irreversible aggregate of platelets which have undergone profound morphological and functional changes. Coagulation testing assesses various aspects of this system and allows healthcare professionals to make appropriate treatment interventions.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.